The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dose delays, dose reductions, and relative dose intensity in patients with cancer who received (neo)adjuvant chemotherapy in community oncology practices.
Menaka Bhor
No relevant relationships to disclose
Xiaoyan Li
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Anne Favret
No relevant relationships to disclose
Phuong Khanh H. Morrow
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Neelima Denduluri
No relevant relationships to disclose
Richard L. Barron
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Shanmugapriya Saravanan
No relevant relationships to disclose
Vincent Girardi
Employment or Leadership Position - Amgen
Consultant or Advisory Role - Amgen
Debra A. Patt
No relevant relationships to disclose
Yanli Li
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Gary H. Lyman
Research Funding - Amgen